title: Experience with International Neuroblastoma Staging System and Pathology Classification.
abstract: The International Neuroblastoma Staging System and Pathology Classification were proposed in 1988 and in 1999, respectively, but their clinical value has not yet been fully studied in new patients. Six hundred and forty-four patients with neuroblastoma treated between January 1995 and December 1999 were analysed by these classifications. The 4-year overall survival rate of patients <12 months of age with INSS stages 1, 2A, 2B, 3 and 4S disease was 98.5%, which was significantly higher than the 73.1% rate in stage 4 patients <12 months (P<0.0001). When patients were > or = 12 months, the 4-year overall survival rate of patients with neuroblastoma at 1, 2A, 2B and 3 stages was 100% and that of patients at stage 4 was 48.5% (P<0.0001). As to the International Neuroblastoma Pathology Classification histology, the 4-year overall survival rate was 98.8% in patients with favourable histology and 60.7% in those with unfavourable histology in the <12 months group (P<0.0001). In the > or = 12 months group, the 4-year oral survival of patients with favourable histology was 95.3% and that of patients with unfavourable histology was 50.6% (P<0.0001). Among biological factors, MYCN amplification, DNA diploidy and 1p deletions were significantly associated with poor prognosis in patients <12 months, as were MYCN amplification and DNA diploidy in patients > or = 12 months of age. Multivariate analysis showed that the INSS stage (stage 4 vs other stages) and International Neuroblastoma Pathology Classification histology (unfavourable vs favourable) were significantly and independently associated with the survival of patients undergoing treatment, stratified by age, stage and MYCN amplification (P=0.0002 and P=0.0051, respectively).
authors.affiliation: Department of Pediatric Surgery, Dokkyo University School of Medicine, Koshigaya Hospital, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama 343-8555, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ikeda
authors.forename: T
authors.initials: T
authors.lastname: Iehara
authors.forename: Y
authors.initials: Y
authors.lastname: Tsuchida
authors.forename: M
authors.initials: M
authors.lastname: Kaneko
authors.forename: J
authors.initials: J
authors.lastname: Hata
authors.forename: H
authors.initials: H
authors.lastname: Naito
authors.forename: M
authors.initials: M
authors.lastname: Iwafuchi
authors.forename: N
authors.initials: N
authors.lastname: Ohnuma
authors.forename: H
authors.initials: H
authors.lastname: Mugishima
authors.forename: Y
authors.initials: Y
authors.lastname: Toyoda
authors.forename: M
authors.initials: M
authors.lastname: Hamazaki
authors.forename: J
authors.initials: J
authors.lastname: Mimaya
authors.forename: S
authors.initials: S
authors.lastname: Kondo
authors.forename: K
authors.initials: K
authors.lastname: Kawa
authors.forename: A
authors.initials: A
authors.lastname: Okada
authors.forename: E
authors.initials: E
authors.lastname: Hiyama
authors.forename: S
authors.initials: S
authors.lastname: Suita
authors.forename: H
authors.initials: H
authors.lastname: Takamatsu
mesh_terms: D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D004273:DNA, Neoplasm / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D005784:Gene Amplification; D016259:Genes, myc; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007391:International Cooperation; D008297:Male; D009367:Neoplasm Staging / Q000379:methods*; D009447:Neuroblastoma / Q000145:classification* / Q000235:genetics / Q000473:pathology*; D011003:Ploidies; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D004273:DNA, Neoplasm